Direxion Daily S&P Biotech Bull 3X ETF
LABU
47 hedge funds and large institutions have $34.5M invested in Direxion Daily S&P Biotech Bull 3X ETF in 2022 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 11 increasing their positions, 9 reducing their positions, and 6 closing their positions.
285% more call options, than puts
Call options by funds: $69.2M | Put options by funds: $18M
250% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 6
47% more funds holding
Funds holding: 32 → 47 (+15)
22% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 9
0.03% less ownership
Funds ownership: 0.2% → 0.17% (-0.03%)
19% less capital invested
Capital invested by funds: $42.4M → $34.5M (-$7.95M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Simplex Trading
Chicago,
Illinois
|
+$9.06M |
| 2 |
AIP
Ahrens Investment Partners
Lafayette,
Louisiana
|
+$3.87M |
| 3 |
HF
HRT Financial
New York
|
+$3.46M |
| 4 |
LJAC
L.J. Altfest & Co
New York
|
+$1.74M |
| 5 |
Millennium Management
New York
|
+$985K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$2.85M |
| 2 |
TCM
Traynor Capital Management
Malvern,
Pennsylvania
|
-$2.39M |
| 3 |
Jane Street
New York
|
-$2.36M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.44M |
| 5 |
Wolverine Trading
Chicago,
Illinois
|
-$1.08M |
LABU Hedge Fund Activity: Q2 2022 in Review
47 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Direxion Daily S&P Biotech Bull 3X ETF (LABU) for Q2 2022, worth a combined $34.5M — down 19% from $42.4M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new LABU positions and 6 closed out — a net gain of 15 holders — while 11 added to existing stakes and 9 trimmed.
The largest buyer was Simplex Trading, adding an estimated $9.06M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $2.85M sold.
- 47 institutional investors held Direxion Daily S&P Biotech Bull 3X ETF (LABU) as of Q2 2022, up from 32 in Q1 2022.
- Funds reported $34.5M of Direxion Daily S&P Biotech Bull 3X ETF stock for Q2 2022, down 19% quarter-over-quarter.
- 21 funds opened new Direxion Daily S&P Biotech Bull 3X ETF positions in Q2 2022 and 6 closed out, a net change of +15 holders.
- The largest Direxion Daily S&P Biotech Bull 3X ETF buyer in Q2 2022 was Simplex Trading, an estimated $9.06M added.
- The largest Direxion Daily S&P Biotech Bull 3X ETF seller in Q2 2022 was Renaissance Technologies, an estimated $2.85M sold.
Based on aggregated 13F filings for Q2 2022.